<h1>U.S. Launches Section 232 Investigations into Chip Production and Pharmaceuticals While Pausing Most Tariff Increases</h1> The Trump administration has initiated investigations into computer chips, chipmaking equipment, and pharmaceuticals for potential tariffs, citing national security concerns under Section 232 of the Trade Expansion Act. While pausing most tariff hikes for 90 days, the administration excluded China and confirmed plans for sector-specific tariffs on pharmaceuticals, semiconductors, and autos that are 'not available for negotiation.' The Commerce Department is examining domestic production capacity, foreign manufacturing dependencies, and risks of concentrated production overseas. The US produces 20% of global pharmaceuticals but consumes 45%, with heavy reliance on foreign suppliers. For advanced chips, the US depends significantly on Taiwan and South Korea. Separately, the administration withdrew from a 2019 agreement on Mexican tomato imports.